PP presentationQuestions from the PP presentation:
"More than 300 peer reviewed papers reporting on more than 10,000 patients.More than 170,000 treatments around the world, less than 0.1% rate of SAE". What is SAE? This is from the company's PP presentation!:
"Spectral is running a PMX confirmatory trial, in order to launch in $1.5B US market in 2021". This from company's "Investors Overview":
More than one million patients in the United States are diagnosed with sepsis each year. Approximately one third of these patients progress to severe sepsis and septic shock, representing a significant unmet need and an approximately $3 billion market opportunity for Spectral.
Why the difference in "market opportunity"
Why is there a need to create a "wholly owned subsidiary" (Dialco)?
"$15-30K per EAA+PMX treatment price models". Does anyone think that this price will come down with demand (better technology to make the cartridges?).
Thanks.